MetLife, Inc. filings document the regulatory record of a Delaware financial services company with NYSE-listed common stock and preferred securities, including depositary shares tied to Series E and Series F preferred stock. Recent Form 8-K reports furnish earnings releases, quarterly financial supplements, total assets under management fact sheets and Regulation FD disclosures related to variable investment income.
The filings also cover capital-structure actions such as subordinated debenture issuance and preferred stock dividend declarations. Proxy materials describe board composition, committee assignments, executive compensation and shareholder voting matters, while material-event reports record governance changes and other corporate disclosures.
Glaser Daniel S reported acquisition or exercise transactions in this Form 4 filing.
MetLife Inc. director Daniel S. Glaser reported a stock-based compensation award of 587 shares of MetLife common stock, valued at $87.40 per share. This award is part of non-management director retainer fees that are paid in MetLife common stock.
After this grant, Glaser directly holds 2,695 MetLife common shares. He also has an additional 198 shares held indirectly through a grantor retained annuity trust (GRAT). The director elected to defer receipt of the awarded shares under the MetLife Deferred Compensation Plan for Non-Management Directors.
MetLife Inc. director Mark A. Weinberger acquired 587 shares of common stock on June 16, 2026 through a grant tied to non-management director retainer fees, rather than a cash purchase. After this award, he directly holds 19,388 MetLife common shares.
MetLife submitted a Form 144 notice reporting proposed sales of Common Stock by affiliated accounts. The filing lists multiple account-level proposed dispositions with trade dates such as 03/20/2026, 04/02/2026, 05/05/2026, and 05/28/2026.
The excerpt shows per-account examples including Separate Account II proposing 145 shares on 03/20/2026 and Separate Account SPI proposing 100 shares on 03/20/2026. The filing is a notice of proposed resale activity; cash‑flow treatment and aggregate registered total are not stated in the provided excerpt.
MetLife filed a Form 144 reporting proposed sales of Common Stock through broker(s) and institutional separate accounts. The filing lists broker Cantor Fitzgerald & Co. and shows multiple recent transactions with dates and share counts.
Examples shown include Separate Account SPI selling 100 shares on 03/20/2026 and Separate Account II selling 144 shares on 05/05/2026.
MetLife Inc. director Diana McKenzie reported an automatic share award linked to deferred compensation. She acquired 169 shares of common stock at an imputed price of $85.57 per share through reinvestment of dividends on deferred shares under the MetLife Deferred Compensation Plan for Non-Management Directors. Following this routine compensation-related acquisition, she holds 24,642 shares of MetLife common stock directly.
MetLife Inc. director William E. Kennard reported an additional grant-related acquisition of common stock. On June 9, 2026, he acquired 322 shares of MetLife common stock at $85.57 per share through imputed reinvestment of dividends on deferred shares under the MetLife Deferred Compensation Plan for Non-Management Directors. Following this transaction, he holds 46,823 common shares directly. The filing also notes 10 common shares held indirectly in the MetLife Policyholder Trust established for eligible policyholders.
MetLife Inc. director Laura J. Hay reported an acquisition of 39 shares of MetLife common stock on a Form 4. The shares were credited at a reference price of $85.57 per share through imputed dividend reinvestment under the MetLife Deferred Compensation Plan for Non-Management Directors, rather than an open-market purchase. Following this routine compensation-related award, Hay directly holds 5,731 MetLife common shares.
MetLife Inc. director Jeh C. Johnson reported an acquisition of 61 shares of MetLife common stock through an imputed reinvestment of dividends on deferred shares under the MetLife Deferred Compensation Plan for Non-Management Directors at a reference price of $85.57 per share.
Following this award-related transaction, Johnson directly holds 8,911 shares of MetLife common stock. The filing reflects a routine, compensation-linked increase in his equity position rather than an open-market purchase.
MetLife Inc. director Carla A. Harris reported a small stock-based compensation increase. On the reported date, she acquired 42 shares of MetLife common stock at $85.57 per share through imputed reinvestment of dividends on deferred shares under the MetLife Deferred Compensation Plan for Non-Management Directors. Following this award, she directly holds 10,528 common shares.
MetLife Inc. director Christian Stephane Mumenthaler reported an acquisition of 20 shares of MetLife common stock on a grant/award basis at $85.57 per share. The footnote explains this was an imputed reinvestment of dividends on deferred shares under the MetLife Deferred Compensation Plan for Non-Management Directors. Following this transaction, he directly holds 2,865 shares of MetLife common stock.